Relapse Management in Multiple Sclerosis

@article{Thrower2009RelapseMI,
  title={Relapse Management in Multiple Sclerosis},
  author={Ben W Thrower},
  journal={The Neurologist},
  year={2009},
  volume={15},
  pages={1-5}
}
  • Ben W Thrower
  • Published 1 January 2009
  • Medicine, Psychology
  • The Neurologist
Relapses, exacerbations, and attacks are synonymous for new or worsened neurologic symptoms that are the hallmark of relapsing-remitting multiple sclerosis. Management of relapses is not always straightforward. The clinician must distinguish between true relapses, symptom fluctuation, and pseudo-relapses. Risks and benefits of treating a relapse must be considered. Once the decision to treat is made, most clinicians would pursue a course of corticosteroids. Consensus may end there, as there is… 
View on Wolters Kluwer
ccs01.vo.ca-cncx.net
44 Citations
Highly Influential Citations
2
Background Citations
22

44 Citations

Therapeutic Management of Severe Relapses in Multiple Sclerosis

In exceptional cases, particularly fulminant or tumefactive disease that fails to improve following treatment with steroids and PLEX, cytoxic agents such as cyclophosphamide or B cell-depleting regimens such as rituximab may be considered, although risk must be carefully weighed and the kinetics of such regimens indicate that they probably serve more to accelerate remission of disease activity than as an immediate relapse remedy.

Repository corticotropin injection in multiple sclerosis: an update.

  • C. KutzAmy Dix
  • Medicine, Psychology
    Neurodegenerative disease management
  • 2018
The most commonly used treatment for multiple sclerosis relapse is a 3-5-day course of corticosteroids, primarily intravenous methylprednisolone with or without oral steroid taper.

Multiple sclerosis- diagnosis, management and prognosis.

The diagnosis, management and prognosis of multiple sclerosis is summarized, supported by investigations including magnetic resonance imaging and lumbar puncture and evoked potentials.

Treatment Effectiveness for Resolution of Multiple Sclerosis Relapse in a US Health Plan Population

A retrospective analysis of patients ages 18–89 years experiencing MS relapse from 1 January 2008 to 30 June 2015 found OCS were generally effective, however, real-world effectiveness varied with other treatments.

Assessing relapses and response to relapse treatment in patients with multiple sclerosis: a nursing perspective.

A brief but comprehensive objective assessment tool that can be used in practice to help clinicians assess patients when they present with symptoms of a relapse, and evaluate outcomes of acute management is described.

Updates on Clinically Isolated Syndrome and Diagnostic Criteria for Multiple Sclerosis

Clinically isolated syndrome (CIS) is a central nervous system demyelinating event isolated in time that is compatible with the possible future development of multiple sclerosis (MS) and magnetic resonance imaging (MRI) is currently the most useful tool to evaluate risk.

Disease Modifying Agents in the Treatment of Multiple Sclerosis

All currently approved disease-modifying agents (DMA) are moderately effective in reducing relapses and MRI activity and the effect on long-term disability seems to be modest if any.

Multiple Sclerosis, Relapses, and the Mechanism of Action of Adrenocorticotropic Hormone

An increased understanding of the role of the melanocortin system, particularly ACTH, in the immune and inflammatory processes underlying relapses may help to improve relapse management.

Understanding treatment decisions from the perspective of people with relapsing remitting multiple Sclerosis: A critical interpretive synthesis.

Intravenous Immunoglobulins Are a Therapeutic Option in the Treatment of Multiple Sclerosis Relapse

Intravenous immunoglobulin did not show inferiority compared with IVMP in the treatment of an acute MS relapse evaluated clinically and radiologically, and it is suggested that IVIG may be tried as a therapy in acuteMS relapse, especially in case of contraindications to IVMP and plasmapheresis.

References

SHOWING 1-10 OF 50 REFERENCES

The incomplete nature of multiple sclerosis relapse resolution

  • F. Lublin
  • Psychology
    Journal of the Neurological Sciences
  • 2007

Natural history of multiple sclerosis.

Corticosteroids or ACTH for acute exacerbations in multiple sclerosis.

Evidence favouring the corticosteroid MP for acute exacerbation in MS patients is found and studies assessing long term risk/benefit and adverse effects of Corticosteroids in MS Patients are urgently needed.

High dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effect.

The integrity of the blood-brain barrier (BBB) in multiple sclerosis (MS) was monitored by serial gadolinium-(Gd)-DTPA enhanced MRI during and after the treatment of acute relapses with a three day…

Treatment with methylprednisolone in relapses of multiple sclerosis patients: immunological evidence of immediate and short‐term but not long‐lasting effects

Results support that MP treatment of relapses induces immediate post‐treatment and short‐term effects on the immune system that could partly account for the clinical and radiological improvement observed in MS patients, however, no conclussion can be drawn as to a possible long‐term or even intermediate influence of ivMP treatment on the course of the disease.

Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis

Using the new McDonald criteria more than doubled the rate of diagnosis of MS within a year of presentation with a clinically isolated syndrome and the high specificity, positive predictive value, and accuracy of the new criteria for clinically definite MS support their clinical relevance.

Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.

Interferon beta-1b 250 μg subcutaneously every other day delayed conversion to clinically definite multiple sclerosis, and should be considered as a therapeutic option in patients presenting with a first clinical event suggestive of multiple sclerosis.

Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials.

Steroid treatment is effective in accelerating short-term recovery in patients with multiple sclerosis or optic neuritis and whether steroids are also effective in reducing the risk of relapse, and the optimal dose and length of treatment must still be determined.

The risk of relapses in multiple sclerosis during systemic infections

There was a significant association between systemic infections and risk of MS relapse, increased MRI activity, and T cells activation, and infectious agents increased myelin specific T-cells sensitivity to cognate Ag.